OXTR and neoplasm: Single-cell RNA-seq of circulating tumor cells and 10× Visium spatial transcriptomics identified OXT/OXTR pathway activation; an in silico FDA-drug screen flagged the antitussive cloperastine, which inhibited DU145-CBZ-resistant growth, synergised with cabazitaxel (combination index < 1), and reduced xenograft burden while suppressing pathway-phosphorylation sites [117].